Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary

Status Terminated

Clinical Trial Summary

Medullary thyroid carcinoma (MTC) is a rare tumor arising from C cells of the thyroid gland and belonging to the endocrine tumors. 18F-DOPA PET, based on tha capacity of endocrine tumor cells to take-up, decarboxylate and store amino-acids, such 3-4-dihydroxyphenylalanine(DOPA), is used for imaging endocrine tumors. The aim of the study was to evaluate the contribution of 18F-DOPA whole-body PET for the detection of recurrences in patients with proven recurrent MTC without evidence of recurrence or metastases on several imaging modalities.

Clinical Trial Description

In patients MTC and persistently elevated calcitonin levels, the challenge is finding the site of residual disease. Since the only satisfying treatment is surgery, the early detection and precise location is important. Tumor localization techniques usually performed, including ultrasonography of the neck and liver, chest and abdomen, bone scintigraphy, isotopic scanning and even PET with FDG are poorly sensitive. The use of 18F-DOPA may be more sensitive and specific engineering for localization metastatic disease. The study include 100 patient with persistent MTC demonstrated by elevated tumor markers (calcitonin and CEA) and no evidence of recurrence on morphological imaging procedures. 18F-DOPA whole-body PET is performed 30 minutes after IV injection of 4 MBq/kg of 18F-DOPA, the patient fasted for 6 hours prior the start of the examination.

All 18F-DOPA PET are evaluated independently by two experienced nuclear medicine physicians and any tracer accumulation exceeding the normal uptake tissue is rated as pathologic finding. The sensibility and efficiency of 18F-DOPA PET will be analysed and Malignant tissue confirmed by histology after surgery or biopsy or by follow-up for one year. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00647140
Study type	Interventional
Source	Assistance Publique - Hôpitaux de Paris
Contact
Status	Terminated
Phase	Phase 2
Start date	August 2007
Completion date	February 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02658513` - Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
Withdrawn	`NCT01707056` - The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma	N/A
Completed	`NCT00215605` - Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies	Phase 1
Terminated	`NCT04327999` - Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System	Phase 2
Completed	`NCT02194920` - Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function	N/A
Enrolling by invitation	`NCT06095362` - Thyroid Cancer and Central Lymph Node Metastases Detection Using Bevacizumab-IRDye800CW	Phase 1
Not yet recruiting	`NCT05949424` - OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults	Phase 4
Active, not recruiting	`NCT02145143` - Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study	N/A
Terminated	`NCT01865838` - A Study Into the Effect of Seprafilm in Open Total Thyroidectomy	N/A
Recruiting	`NCT00749697` - Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases	N/A
Enrolling by invitation	`NCT04411290` - Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases
Completed	`NCT01813136` - Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma	Phase 2
Recruiting	`NCT05668962` - Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC	Phase 2
Active, not recruiting	`NCT02185560` - Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
Completed	`NCT04462471` - Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers	Phase 1
Completed	`NCT01433809` - Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm	N/A
Recruiting	`NCT00929318` - Influence of Thyroid Hormones on the Woundhealing Process	N/A
Completed	`NCT05178186` - Impact of the COVID-19 Pandemic on Surgery for Thyroid Cancer	N/A
Completed	`NCT02773667` - Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine
Not yet recruiting	`NCT00993837` - Feasibility of Endoscopic Thyroidectomy for Thyroid Carcinoma	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer — DOPMET

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms